- Home
- DOMH vs IGMS Comparison
DOMH vs IGMS Comparison
Compare DOMH & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOMH
- IGMS
- Stock Information
- Founded
- DOMH 1967
- IGMS 1993
- Country
- DOMH United States
- IGMS United States
- Employees
- DOMH N/A
- IGMS N/A
- Industry
- DOMH Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- DOMH Health Care
- IGMS Health Care
- Exchange
- DOMH Nasdaq
- IGMS Nasdaq
- Market Cap
- DOMH 68.4M
- IGMS 82.1M
- IPO Year
- DOMH N/A
- IGMS 2019
- Fundamental
- Price
- DOMH $5.91
- IGMS $1.18
- Analyst Decision
- DOMH
- IGMS Hold
- Analyst Count
- DOMH 0
- IGMS 8
- Target Price
- DOMH N/A
- IGMS $6.14
- AVG Volume (30 Days)
- DOMH 300.4K
- IGMS 150.9K
- Earning Date
- DOMH 05-27-2025
- IGMS 05-27-2025
- Dividend Yield
- DOMH 5.41%
- IGMS N/A
- EPS Growth
- DOMH N/A
- IGMS N/A
- EPS
- DOMH N/A
- IGMS N/A
- Revenue
- DOMH $24,891,000.00
- IGMS $2,681,000.00
- Revenue This Year
- DOMH N/A
- IGMS $121.76
- Revenue Next Year
- DOMH N/A
- IGMS $46.83
- P/E Ratio
- DOMH N/A
- IGMS N/A
- Revenue Growth
- DOMH 789.95
- IGMS 25.77
- 52 Week Low
- DOMH $0.83
- IGMS $0.92
- 52 Week High
- DOMH $13.58
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- DOMH 57.32
- IGMS 45.45
- Support Level
- DOMH $5.36
- IGMS $1.08
- Resistance Level
- DOMH $6.21
- IGMS $1.23
- Average True Range (ATR)
- DOMH 0.54
- IGMS 0.08
- MACD
- DOMH 0.06
- IGMS -0.01
- Stochastic Oscillator
- DOMH 64.36
- IGMS 31.25
About DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.